Inflammatory factors of the tumor microenvironment nduce plasticity in nontransformed breast epithelial cells: EMT, invasion, and collapse of normally organized breast textures

Neoplasia (United States)

Volumn 15, Issue 12, 2013, Pages 1330-1346

  Leibovich Rivkin, Tal ^a   Liubomirski, Yulia ^a   Bernstein, Biana ^a   Meshel, Tsipi ^a   Ben Baruch, Adit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; HYGROMYCIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NEOMYCIN; PUROMYCIN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; VIMENTIN;

ARTICLE; BREAST TUMOR; CANCER RECURRENCE; CELL INVASION; CELL STRUCTURE; CONFOCAL LASER MICROSCOPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; NERVE CELL PLASTICITY; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TUMOR MICROENVIRONMENT; WOUND HEALING; ZYMOGRAPHY;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SHAPE; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; MAMMARY GLANDS, HUMAN; NEOPLASM INVASIVENESS; TRANSCRIPTION FACTORS; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891585956     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.131688     Document Type: Article

References (97)

1. Colotta F, Allavena P, Sica A, Garlanda C, and Mantovani A (2009). Cancerrelated inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30, 1073-1081.
2. Allavena P, Sica A, Solinas G, Porta C, and Mantovani A (2007). The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66, 1-9.
3. Jiang X and Shapiro DJ (2013). The immune system and inflammation in breast cancer. Mol Cell Endocrinol 382, 673-682.
4. Goldberg JE and Schwertfeger KL (2013). Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 11, 1133-1146.
5. Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, et al. (1997). Expression of interleukin-1beta in human breast carcinoma. Cancer 80, 421-434.
6. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D, Roques S, and Lazennec G (2007). Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 9, R15.
7. Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, Kurtzman SH, Barrows G, and Kreutzer DL (2003). The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol 23, 269-284.
8. Abrahamsson A, Morad V, Saarinen NM, and Dabrosin C (2012). Estradiol, tamoxifen, and flaxseed alter IL-1β and IL-1Ra levels in normal human breast tissue in vivo. J Clin Endocrinol Metab 97, E2044-E2054.
9. Kurtzman SH, Anderson KH, Wang Y, Miller LJ, Renna M, Stankus M, Lindquist RR, Barrows G, and Kreutzer DL (1999). Cytokines in human breast cancer: IL-1alpha and IL-1beta expression. Oncol Rep 6, 65-70.
10. Leek RD, Landers R, Fox SB, Ng F, Harris AL, and Lewis CE (1998). Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 77, 2246-2251.
11. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, and Balkwill FR (1994). Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer 56, 777-782.
12. García-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R, and Royuela M (2006). Role of tumor necrosis factor-α and its receptors in human benign breast lesions and tumors (in situ and infiltrative). Cancer Sci 97, 1044-1049.
13. El Agouza IM, Eissa SS, El Houseini MM, El-Nashar DE, and Abd El Hameed OM (2011). Taurine: a novel tumor marker for enhanced detection of breast cancer among female patients. Angiogenesis 14, 321-330.
14. Cui LF, Guo XJ, Wei J, Liu FF, Fan Y, Lang RG, Gu F, Zhang XM, and Fu L (2008). Overexpression of TNF-α and TNFRII in invasive micropapillary carcinoma of the breast: clinicopathological correlations. Histopathology 53, 381-388.
15. Sheen-Chen SM, Chen WJ, Eng HL, and Chou FF (1997). Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 43, 211-215.
16. Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich- Rivkin T, Weitzenfeld P, Meshel T, Shabtai E, Gutman M, et al. (2011). Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 11, 130-149.
17. Hagemann T, Robinson SC, Schulz M, Trümper L, Balkwill FR, and Binder C (2004). Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-α dependent up-regulation of matrix metalloproteases. Carcinogenesis 25, 1543-1549.
18. Warren MA, Shoemaker SF, Shealy DJ, Bshar W, and Ip MM (2009). Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice. Mol Cancer Ther 8, 2655-2663.
19. Sangaletti S, Tripodo C, Ratti C, Piconese S, Porcasi R, Salcedo R, Trinchieri G, Colombo MP, and Chiodoni C (2010). Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis. Cancer Res 70, 7764-7775.
20. Romieu-Mourez R, Francois M, Abate A, Boivin MN, Birman E, Bailey D, Bramson JL, Forner K, Young YK, Medin JA, et al. (2010). Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-γ and tumor necrosis factor-α priming. Cancer Res 70, 7742-7747.
21. Hamaguchi T, Wakabayashi H, Matsumine A, Sudo A, and Uchida A (2011). TNF inhibitor suppresses bone metastasis in a breast cancer cell line. Biochem Biophys Res Commun 407, 525-530.
22. Rubio MF, Werbajh S, Cafferata EG, Quaglino A, Colo GP, Nojek IM, Kordon EC, Nahmod VE, and Costas MA (2006). TNF-α enhances estrogeninduced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B. Oncogene 25, 1367-1377.
23. Rivas MA, Tkach M, Beguelin W, Proietti CJ, Rosemblit C, Charreau EH, Elizalde PV, and Schillaci R (2009). Transactivation of ErbB-2 induced by tumor necrosis factor α promotes NF-κB activation and breast cancer cell proliferation. Breast Cancer Res Treat 122, 111-124.
24. Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W, Salatino M, Charreau EH, Frahm I, Sapia S, Brouckaert P, et al. (2008). TNFα acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-κB-dependent pathways. Exp Cell Res 314, 509-529.
25. Purohit A, Newman SP, and Reed MJ (2002). The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res 4, 65-69.
26. Ben-Baruch A (2012). The tumor-promoting flow of cells into, within and out of the tumor site: regulation by the inflammatory axis of TNFα and chemokines. Cancer Microenviron 5, 151-164.
27. Balkwill F and Mantovani A (2010). Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 87, 401-406.
28. Balkwill FR and Mantovani A (2012). Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 22, 33-40.
29. Mocellin S and Nitti D (2008). TNF and cancer: the two sides of the coin. Front Biosci 13, 2774-2783.
30. Reed JR, Leon RP, Hall MK, and Schwertfeger KL (2009). Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis. Breast Cancer Res 11, R21.
31. Schmid MC, Avraamides CJ, Foubert P, Shaked Y, Kang SW, Kerbel RS, and Varner JA (2011). Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. Cancer Res 71, 6965-6975.
32. Zhou W, Guo S, and Gonzalez-Perez RR (2011). Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling. Br J Cancer 104, 128-137.
33. Naldini A, Filippi I, Miglietta D, Moschetta M, Giavazzi R, and Carraro F (2010). Interleukin-1β regulates the migratory potential of MDAMB231 breast cancer cells through the hypoxia-inducible factor-1α. Eur J Cancer 46, 3400-3408.
34. Palmieri C, Roberts-Clark D, Assadi-Sabet A, Coope RC, O'Hare M, Sunters A, Hanby A, Slade MJ, Gomm JJ, Lam EW, et al. (2003). Fibroblast growth factor 7, secreted by breast fibroblasts, is an interleukin-1β-induced paracrine growth factor for human breast cells. J Endocrinol 177, 65-81.
35. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, and Voronov E (2006). The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25, 387-408.
36. Voronov E, Carmi Y, and Apte RN (2007). Role of IL-1-mediated inflammation in tumor angiogenesis. Adv Exp Med Biol 601, 265-270.
37. Dinarello CA (2010). Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev 29, 317-329.
38. Dong R, Wang Q, He XL, Chu YK, Lu JG, and Ma QJ (2007). Role of nuclear factor kappa B and reactive oxygen species in the tumor necrosis factor-alphainduced epithelial-mesenchymal transition of MCF-7 cells. Braz J Med Biol Res 40, 1071-1078.
39. Zhou C, Nitschke AM, Xiong W, Zhang Q, Tang Y, Bloch M, Elliott S, Zhu Y, Bazzone L, Yu D, et al. (2008). Proteomic analysis of tumor necrosis factor-α resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelialmesenchymal transition phenotype. Breast Cancer Res 10, R105.
40. Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, et al. (2012). Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. Cancer Res 72, 1290-1300.
41. Wang FM, Liu HQ, Liu SR, Tang SP, Yang L, and Feng GS (2005). SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1beta in vivo and in vitro. Breast Cancer Res Treat 89, 5-14.
42. Pérez-Yépez EA, Ayala-Sumuano JT, Reveles-Espinoza AM, and Meza I (2012). Selection of a MCF-7 breast cancer cell subpopulation with high sensitivity to IL-1β: characterization of and correlation between morphological and molecular changes leading to increased invasiveness. Int J Breast Cancer 2012, 609148.
43. Franco-Barraza J, Valdivia-Silva JE, Zamudio-Meza H, Castillo A, Garcia- Zepeda EA, Benitez-Bribiesca L, and Meza I (2010). Actin cytoskeleton participation in the onset of IL-1beta induction of an invasive mesenchymal-like phenotype in epithelial MCF-7 cells. Arch Med Res 41, 170-181.
44. Chaffer CL and Weinberg RA (2011). A perspective on cancer cell metastasis. Science 331, 1559-1564.
45. Sánchez-Tilló E, Liu Y, de Barrios O, Siles L, Fanlo L, Cuatrecasas M, Darling DS, Dean DC, Castells A, and Postigo A (2012). EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci 69, 3429-3456.
46. Tomaskovic-Crook E, Thompson EW, and Thiery JP (2009). Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 11, 213.
47. Vincent-Salomon A and Thiery JP (2003). Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res 5, 101-106.
48. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, and Waltham M (2007). Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tissues Organs 185, 191-203.
49. Jeong H, Ryu YJ, An J, Lee Y, and Kim A (2012). Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triplenegative phenotype. Histopathology 60, E87-E95.
50. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, and Weinberg RA (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939.
51. Karihtala P, Auvinen P, Kauppila S, Haapasaari KM, Jukkola-Vuorinen A, and Soini Y (2013). Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype. Breast Cancer Res Treat 138, 81-90.
52. Liu T, Zhang X, Shang M, Zhang Y, Xia B, Niu M, Liu Y, and Pang D (2013). Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer. J Surg Oncol 107, 188-194.
53. Asiedu MK, Ingle JN, Behrens MD, Radisky DC, and Knutson KL (2011). TGFβ/TNFα-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res 71, 4707-4719.
54. Yamamoto H, Mukaisho K, Sugihara H, Hattori T, and Asano S (2011). Down-regulation of FXYD3 is induced by transforming growth factor-β signaling via ZEB1/δEF1 in human mammary epithelial cells. Biol Pharm Bull 34, 324-329.
55. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, and Nakshatri H (2007). NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 26, 711-724.
56. Debnath J, Muthuswamy SK, and Brugge JS (2003). Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30, 256-268.
57. Lee GY, Kenny PA, Lee EH, and Bissell MJ (2007). Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4, 359-365.
58. Korde Choudhari S, Chaudhary M, Bagde S, Gadbail AR, and Joshi V (2011). Nitric oxide and cancer: a review. World J Surg Oncol 11, 118.
59. Grimm EA, Sikora AG, and Ekmekcioglu S (2013). Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clin Cancer Res 19, 5557-5563.
60. Yakovlev VA (2013). Nitric oxide-dependent downregulation of BRCA1 expression promotes genetic instability. Cancer Res 73, 706-715.
61. Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, and Brooks SC (1990). Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50, 6075-6086.
62. Lacroix M and Leclercq G (2004). Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83, 249-289.
63. Medrek C, Landberg G, Andersson T, and Leandersson K (2009). Wnt-5a- CKIα signaling promotes β-catenin/E-cadherin complex formation and intercellular adhesion in human breast epithelial cells. J BiolChem284, 10968-10979.
64. Berdichevsky F, Alford D, D'Souza B, and Taylor-Papadimitriou J (1994). Branching morphogenesis of human mammary epithelial cells in collagen gels. J Cell Sci 107(pt 12), 3557-3568.
65. Bertazza L, Mocellin S, DeWitte M, and Nitti D (2012). TNF and cancer: friends and/or foes? In The Inflammatory Milieu of Tumors: Cytokines and Chemokines that Affect Tumor Growth and Metastasis. A Ben-Baruch (Ed). Bentham Science Publishers, United Arab Emirates. pp. 29-56.
66. Neumark E, Cohn MA, Lukanidin E, Witz IP, and Ben-Baruch A (2002). Possible co-regulation of genes associated with enhanced progression of mammary adenocarcinomas. Immunol Lett 82, 111-121.
67. Neumark E, Sagi-Assif O, Shalmon B, Ben-Baruch A, and Witz IP (2003). Progression of mouse mammary tumors: MCP-1-TNFα cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. Int J Cancer 106, 879-886.
68. Seeger H, Wallwiener D, and Mueck AO (2006). Different effects of estradiol and various antiestrogens on TNF-α-induced changes of biochemical markers for growth and invasion of human breast cancer cells. Life Sci 78, 1464-1468.
69. Seeger H, Wallwiener D, and Mueck AO (2008). Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis. Gynecol Endocrinol 24, 576-579.
70. Soria G, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, Weitzenfeld P, Meshel T, Shabtai E, Gutman M, and Ben-Baruch A (2011). An inflammatory network in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 11, 130-149.
71. DeLarco JE, Wuertz BR, Rosner KA, Erickson SA, Gamache DE, Manivel JC, and Furcht LT (2001). A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol 158, 639-646.
72. Pantschenko AG, Pushkar I, Miller LJ, Wang YP, Anderson K, Peled Z, Kurtzman SH, and Kreutzer DL (2003). In vitro demonstration of breast cancer tumor cell sub-populations based on interleukin-1/tumor necrosis factor induction of interleukin-8 expression. Oncol Rep 10, 1011-1017.
73. Soria G and Ben-Baruch A (2008). The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267, 271-285.
74. Yadav A, Saini V, and Arora S (2010). MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta 411, 1570-1579.
75. Conti I and Rollins BJ (2004). CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 14, 149-154.
76. Waugh DJ and Wilson C (2008). The interleukin-8 pathway in cancer. Clin Cancer Res 14, 6735-6741.
77. Vandercappellen J, Van Damme J, and Struyf S (2008). The role of CXC chemokines and their receptors in cancer. Cancer Lett 267, 226-244.
78. Ali S and Lazennec G (2007). Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev 26, 401-420.
79. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, and Brabletz T (2008). A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 9, 582-589.
80. Teng Y, Mei Y, Hawthorn L, and Cowell JK (2013). WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells. Oncogene.
81. Yang F, Sun L, Li Q, Han X, Lei L, Zhang H, and Shang Y (2012). SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO J 31, 110-123.
82. Kim T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, Volinia S, Pineau P, Marchio A, Palatini J, Suh SS, et al. (2011). P53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 208, 875-883.
83. Sun M, Guo X, Qian X, Wang H, Yang C, Brinkman KL, Serrano-Gonzalez M, Jope RS, Zhou B, Engler DA, et al. (2012). Activation of the ATM-Snail pathway promotes breast cancer metastasis. J Mol Cell Biol 4, 304-315.
84. Yuen HF, Chan YK, Grills C, McCrudden CM, Gunasekharan V, Shi Z, Wong AS, Lappin TR, Chan KW, Fennell DA, et al. (2011). Polyomavirus enhancer activator 3 protein promotes breast cancer metastatic progression through Snailinduced epithelial-mesenchymal transition. J Pathol 224, 78-89.
85. Riaz M, Sieuwerts AM, Look MP, Timmermans MA, Smid M, Foekens JA, and Martens JW (2013). High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes. Breast Cancer Res 14, R123.
86. Eckert MA, Lwin TM, Chang AT, Kim J, Danis E, Ohno-Machado L, and Yang J (2011). Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 19, 372-386.
87. Banerjee A, Wu ZS, Qian P, Kang J, Pandey V, Liu DX, Zhu T, and Lobie PE (2011). ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma. Breast Cancer Res 13, R112.
88. van Nes JG, de Kruijf EM, Putter H, Faratian D, Munro A, Campbell F, Smit VT, Liefers GJ, Kuppen PJ, van de Velde CJ, et al. (2012). Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients. Breast Cancer Res Treat 133, 49-59.
89. Yuen HF, Zhang SD, Wong AS, McCrudden CM, Huang YH, Chan KY, El-Tanani M, and Khoo US (2012). Regarding "Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients". Breast Cancer Res Treat 131, 351-352.
90. Roxanis I (2013). Occurrence and significance of epithelial-mesenchymal transition in breast cancer. J Clin Pathol 66, 517-521.
91. Montserrat N, Gallardo A, Escuin D, Catasus L, Prat J, Gutierrez-Avigno FJ, Peiro G, Barnadas A, and Lerma E (2011). Repression of E-cadherin by SNAIL, ZEB1, and TWIST in invasive ductal carcinomas of the breast: a cooperative effort? Hum Pathol 42, 103-110.
92. Sirohi B, Leary A, and Johnston SR (2009). Ipsilateral breast tumor recurrence: is there any evidence for benefit of further systemic therapy? Breast J 15, 268-278.
93. Abd-Alla HM, Lotayef MM, Abou Bakr A, and Moneer MM (2006). Ipsilateral in-breast tumor relapse after breast conservation therapy: true recurrence versus new primary tumor. J Egypt Natl Canc Inst 18, 183-190.
94. Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, and Arima N (2011). Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol 9, 131.
95. West NR, Panet-Raymond V, Truong PT, Alexander C, Babinszky S, Milne K, Ross LA, Loken S, and Watson PH (2011). Intratumoral immune responses can distinguish new primary and true recurrence types of ipsilateral breast tumor recurrences (IBTR). Breast Cancer (Auckl) 5, 105-115.
96. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD, and Chodosh LA (2005). The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8, 197-209.
97. Hollier BG, Evans K, and Mani SA (2009). The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 14, 29-43.